Newsroom

Sorted by: Latest

-

Agenus宣布《自然·医学》发表多中心UNICORN二期试验结果:新辅助BOT+BAL在可切除结肠癌中展现深度应答

马萨诸塞州列克星敦--(BUSINESS WIRE)--(美国商业资讯)-- 免疫肿瘤创新领域的领导者Agenus Inc. (Nasdaq: AGEN) 今日宣布,研究者发起的多中心二期UNICORN试验结果经同行评审后正式发表。该试验评估了术前短期(新辅助)botensilimab(BOT,Agenus的多功能Fc增强型抗CTLA-4抗体)单药或联合balstilimab(BAL,Agenus的抗PD-1抗体)用于可切除局部晚期结肠癌患者的疗效。论文题为《术前botensilimab联合或不联合balstilimab治疗可切除局部晚期pMMR或dMMR结肠癌患者:GONO的UNICORN试验》,发表于《自然·医学》(Nature Medicine),DOI:10.1038/s41591-026-04710-1。 UNICORN试验纳入56例患者,分为四个每组14人的非随机队列,评估BOT单药或BOT+BAL在错配修复正常/微卫星稳定(pMMR/MSS)与错配修复缺陷/微卫星高度不稳定(dMMR/MSI-H)结肠癌中的疗效。研究评估了病理应答、无事件生存、循环肿瘤DNA (ctDNA...
-

Agenus anuncia la publicación en Nature Medicine de los resultados del ensayo UNICORN de fase 2, que demuestra respuestas profundas con BOT+BAL en pacientes con cáncer de colon resecable

LEXINGTON, Massachusetts--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), empresa líder en innovación en inmunooncología, anunció hoy la publicación en Nature Medicine de los resultados del ensayo multicéntrico de fase 2 UNICORN, promovido por investigadores. El estudio evaluó un tratamiento neoadyuvante breve con botensilimab (BOT), el anticuerpo anti-CTLA-4 multifuncional con región Fc potenciada de Agenus, solo o combinado con balstilimab (BAL), su anticuerpo anti-PD-1, en pacientes con cáncer...
-

Tri Counties Bank Opens Annual Scholarship Program for High School Seniors

CHICO, Calif.--(BUSINESS WIRE)--Tri Counties Bank, in partnership with the Community Foundation of the North State, is now accepting applications for its annual scholarship program. The program is open to high school seniors graduating in spring 2027 who plan to attend a trade school, community college, or four-year college or university. The program awards students who demonstrate an interest in public service, community engagement, or business entrepreneurship. Two scholarship categories are...
-

Agenus gibt Veröffentlichung der multizentrischen Phase-2-Studie UNICORN in Nature Medicine bekannt: Neoadjuvante Kombination BOT+BAL erzielt starkes Ansprechen beim resektablen Kolonkarzinom

LEXINGTON, Massachusetts, USA--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), ein führendes Unternehmen im Bereich der Immunonkologie, hat heute die Veröffentlichung der Ergebnisse der von Prüfärzten initiierten, multizentrischen Phase-2-Studie UNICORN in einer Fachzeitschrift mit Peer-Review bekannt gegeben. Die Studie untersuchte eine kurzzeitige präoperative (neoadjuvante) Behandlung mit Botensilimab (BOT), dem multifunktionalen, Fc-verstärkten Anti-CTLA-4-Antikörper von Agenus, als Monotherap...
-

Empire State Realty Trust Achieves Highest GRESB Management Score for All Companies in the Americas for Second Consecutive Year, and Top 5-Star Rating

NEW YORK--(BUSINESS WIRE)--Empire State Realty Trust, Inc. (NYSE: ESRT) announced today that it was named Regional Sector Leader and achieved the highest management score for all 529 ranked companies in the Americas. The company achieved the highest possible Global Real Estate Sustainability Benchmark (GRESB) 5 Star Rating for the seventh consecutive year with a score of 92.3 and an A in public disclosure. GRESB is a rigorous standard that assesses and benchmarks the sustainability performance...
-

Empire State Realty Trust Signs Octaura for 28,914 Square Feet at 111 W. 33rd Street

NEW YORK--(BUSINESS WIRE)--Empire State Realty Trust, Inc. (NYSE: ESRT) announced today that it signed Octaura Holdings LLC – an electronic trading, data & analytics provider – for a 28,914 square foot office space on the entire 17th floor at 111 W. 33rd Street. “This new office marks an exciting next chapter for Octaura,” said Brian Bejile, CEO of Octaura. “As we continue to grow our business and our team, it was important to find a space that reflects where we’re headed and gives our peop...
-

Samenvatting: Agenus kondigt publicatie in Nature Medicine aan van zijn Multicenter UNICORN Fase 2-studie, waarin diepe responsen worden aangetoond met neoadjuvant BOT+BAL bij resectabel coloncarcinoom

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), een leider op gebied van innovatie in immuno-oncologie, kondigde vandaag de collegiaal getoetste publicatie aan van resultaten uit de door de onderzoeker geïnitieerde, multicenter Fase 2 UNICORN-studie ter evaluatie van kortdurend preoperatieve, of neoadjuvante, botensilimab (BOT), Agenus’ multifunctionele, Fc-geoptimaliseerde anti-CTLA-4-antilichaam, apart of in combinatie met balstilimab (BAL), Agenus’ anti-PD-1-antilichaam, bij p...
-

Smartly推出Intelligence Pro,整合行銷活動規劃、績效和增量效果助力決策

紐約--(BUSINESS WIRE)--(美國商業資訊)-- 人工智慧廣告科技公司Smartly今天推出「Intelligence Pro」。這款高級解決方案整合四項能力於一處,幫助行銷人員規劃投資、洞察實際增量效果,並決定日後應將資金投入何處。Intelligence Pro結合因果推論模型與規劃工具,協助行銷人員驗證業務成效,在資料日益複雜的現狀下,亦能加速制定決策。 「行銷團隊擁有大量資料,但難處在於如何找出哪些是有用資訊,並轉化為可以導向行動的決策。」Smartly產品長Maxwell Tang說,「Intelligence Pro整合預測、市場脈絡以及先進增量評估訊息,幫助行銷人員判斷投資標的,並找出媒體的實際貢獻。由於人工智慧正在加速執行行銷活動,每項決策的品質也變得愈發重要。」 Intelligence Pro在Smartly平台內整合四大功能: 覆蓋率規劃工具幫助團隊在行銷活動啟動前比較各類媒體方案,並預測跨通路覆蓋率與頻率以做出更明智的決策。 成長餘裕分析幫助行銷人員評估提高哪些領域的投資有望推動成長,以及哪些領域的投資回報可能會開始遞減。 績效基準使用匯總和匿名資...
-

Riassunto: Agenus annuncia la pubblicazione su Nature Medicine dello studio clinico multicentrico di fase 2 UNICORN, volto a dimostrare risposte profonde con il neoadiuvante BOT+BAL nel carcinoma del colon resecabile

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. leader nell’innovazione nel campo dell’immuno-oncologia, oggi ha annunciato la pubblicazione, sottoposta a revisione paritaria, dei risultati dello studio multicentrico di fase 2 UNICORN, sponsorizzato dai ricercatori, volto a valutare un ciclo breve di trattamento preoperatorio, o neoadiuvante, con botensilimab (BOT), l’anticorpo anti-CTLA-4 multifunzionale potenziato con Fc di Agenus, in monoterapia o in combinazione con balstilimab (BAL), l’anti...
-

Smartly推出Intelligence Pro,联通广告活动规划、效果评估与增量分析

纽约--(BUSINESS WIRE)--(美国商业资讯)-- Smartly——AI驱动的广告技术公司今日推出高端服务Intelligence Pro。该服务整合四项功能,帮助营销人员规划广告投入、了解真实增量效果,并确定下一笔预算投向何处。Intelligence Pro还将因果推断模型与规划工具相结合,使营销人员能够验证广告对业务的实际影响,并基于日益复杂的数据更快做出决策。 Smartly首席产品官Maxwell Tang表示:“营销团队面对海量数据,难点在于识别哪些信号真正有用,并把这些信号转化为可执行的决策。Intelligence Pro整合了预测分析、市场背景信息和先进的增量效果信号,帮助营销人员评估投资方向和媒体投放的实际贡献。随着AI加快广告活动的执行速度,每项决策的质量也变得更加重要。” Intelligence Pro在Smartly平台中整合了四项功能: Reach Planner帮助团队比较不同的媒体投放方案,并在广告活动启动前预测跨渠道触达人数和频次,为规划提供依据。 Headroom Analysis帮助营销人员判断增加投入还有多大机会带动增长,以及在哪...